Luke H. Johnson

Luke H. Johnson

Auto-generated profile, based on publicly available information

Luke H. Johnson

University of Louisville School of Medicine, Louisville, Kentucky, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in JID Innovations
Verified
Journal Article
Open access
LJLuke H. Johnson
Luke H. Johnson
HSHeehwa G. Son
Heehwa G. Son
DHDat Thinh Ha
Dat Thinh Ha
JSJohn D. Strickley
John D. Strickley
JJJoongho John Joh
Joongho John Joh
SDShadmehr Demehri
Shadmehr Demehri
Cutaneous squamous cell carcinoma (cSCC) is the second most common cancer, with increased incidence in immunosuppressed patients. β-Human papillomavirus has been proposed as a contributor to cSCC risk partly on the basis of increased β-human papillomavirus viral load and seropositivity observed among patients with cSCC. Experimental data in mice colonized with mouse papillomavirus type 1 suggest that T cell immunity against β-human papillomavirus suppresses skin cancer in immunocompetent hosts, and the loss of this immunity leads to the increased risk of cSCC. In this study, we show that CD8+ T cell depletion in mouse papillomavirus type 1‒colonized mice that underwent skin carcinogenesis protocol led to increased viral load in the skin and seropositivity for anti‒mouse papillomavirus type 1 antibodies. These findings provide evidence that compromised T cell immunity can be the link that connects increased β-human papillomavirus detection to cSCC risk.

26 September 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
LJLuke Johnson
Luke Johnson
DHDat T. Ha
Dat T. Ha
MHMelissa B. Hall
Melissa B. Hall
GSGregory Shoemaker
Gregory Shoemaker
PBPaul A. Bevins
Paul A. Bevins
JJJoongho John Joh
Joongho John Joh
High-risk human papillomavirus (HPV) is among the most common causes of head and neck cancer (HNC) with increasing incidence. HPV-associated HNC patients’ clinical response to treatment varies drastically, which has made treatment de-escalation clinical trials challenging. To address the need for noninvasive biomarkers that differentiate patient outcomes, serum antibodies to E7 oncoprotein levels were evaluated in serial serum specimens from HPV-positive HNC patients ( ). We have found that increasing antibodies to E7 throughout treatment correlates with increased cancer recurrence or progression to mortality ( ) with 100% specificity as a predictive test.